Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates.
Tabor, D.E., Oganesyan, V., Keller, A.E., Yu, L., McLaughlin, R.E., Song, E., Warrener, P., Rosenthal, K., Esser, M., Qi, Y., Ruzin, A., Stover, C.K., DiGiandomenico, A.(2018) J Infect Dis 218: 1983-1994
- PubMed: 30016475 
- DOI: https://doi.org/10.1093/infdis/jiy438
- Primary Citation of Related Structures:  
6CYF - PubMed Abstract: 
Bispecific antibody MEDI3902, targeting the Pseudomonas aeruginosa type 3 secretion system (PcrV) and Psl exopolysaccharide, is currently in phase 2b development for prevention of nosocomial pneumonia in patients undergoing mechanical ventilation. We surveyed a diverse collection of isolates to study MEDI3902 epitope conservation and protective activity.
Organizational Affiliation: 
Translational Medicine, Gaithersburg, Maryland.